2024 Sponsors

Platinum sponsors

AbbVie

In the field of neuroscience, with many tough-to-treat disorders and high unmet need, our scientists are relentless in their pursuit of raising the standards of care. But the brain is complex, and new challenges require new ways of thinking across all stages of drug discovery and development.

That’s why we are continuously exploring innovative, disease-modifying approaches to address some of the most prevalent and serious disorders, from Parkinson’s and Alzheimer’s to migraine, schizophrenia and stroke.

We work across all stages of development in search of novel therapeutics and drug-device combinations that have the potential to treat chronic disabling neurological and psychiatric conditions.

Merck

Merck, a leading science and technology company operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in Multiple Sclerosis (MS). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck’s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have potrential inthat have potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE) and generalized myasthenia gravis (gMG).

SILVER sponsor

Roche

Since our founding over 125 years ago, Roche has grown into one of the world’s largest biotech companies, as well as a leading provider of in-vitro diagnostics and a global supplier of transformative innovative solutions across major disease areas. Our commitment to our people, partners, stakeholders and, most importantly, our patients remains as strong as it was on the first day of our journey.

sponsor

Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Our strategy is to deliver high value medicines that alleviate society’s greatest disease burdens through technology leadership in R&D and novel access approaches.

We focus on core therapeutic areas with high unmet patient needs – cardiovascular, renal and metabolic, immunology, neuroscience and oncology.